large numbers of us women stopped taking hormone therapies ht especially estrogenprogestin ep formulations after the womens health initiative trial detected elevated risks of breast cancer in ep users and was halted in july 2002recent reports have indicated substantial and significant declines in populationbased breast cancer incidence particularly hormonesensitive forms for 2003 and 2004are these events linkedthis commentary considers the available evidence linking the mass cessation of ht in 2002 to the breast cancer incidence declines of 20032004 and quantifies the potential impact of the cessation on the overall burden of breast cancer in the us